Regarding this effect, a clinical trial has been studied using a novel long-acting FGF21 pegbelfermin which may have therapeutic effects on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis [24]. This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatohepatitis.